Natural history and treatment of cutaneous and systemic mastocytosis

Le, Michelle; Miedzybrodzki, Barbara; Olynych, Tim; Chapdelaine, Hugo; Ben‐Shoshan, Moshe

doi:10.1080/00325481.2017.1364124

Cited by 39 publications

(39 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous canine CM reports showed good to excellent response to H1 and H2 blockers and resolution of lesions; in one dog lesions persisted but antihistamine controlled pruritus and recurrent flares . In humans, rapid resolution of maculopapular CM skin lesions is seen with topical glucocorticoids . Although systemic glucocorticoids are routinely integrated into the treatment of MCTs in dogs, data on their use in canine CM is scarce.…”

Section: Discussionmentioning

confidence: 99%

Lokivetmab therapy for pruritus in a dog with cutaneous mastocytosis

Meichner

Kiupel

Kasantikul

et al. 2018

Veterinary Dermatology

View full text Add to dashboard Cite

Background Cutaneous mastocytosis (CM) is a rare disease of dogs characterized by rash, pruritus and proliferation of mast cells in the skin. Oral H1 antihistamines are recommended as the treatment to control pruritus. Hypothesis/Objective To describe the effective treatment of pruritus associated with CM with lokivetmab in one dog. Animal A 4‐year‐old, spayed female cross‐bred dog presented with severely pruritic, erythematous to pigmented macules and papules involving the ventral abdomen, interdigital skin, perivulval area and both pinnae; the pruritus had been unresponsive to treatment with antihistamines, prednisone and ciclosporin. Methods and materials Complete blood count and serum biochemistry, abdominal ultrasound, blood smear and skin cytological evaluation, PCR, histopathological and immunohistochemical examination of skin biopsies. Results Skin cytological evaluation revealed high numbers of uniform, heavily granulated mast cells; histopathological findings showed focal dermal proliferations of well‐differentiated, uniform mast cells consistent with a low‐grade mast cell tumour (MCT). Clinical staging revealed that the disease was confined to the skin. Mutations of c‐kit exon 8 and 11 were not detected. Treatment was initiated with anti‐canine‐interleukin (IL)‐31 monoclonal antibody lokivetmab; antihistamines were continued. The dog's pruritus resolved within seven days and was maintained in remission over 15 months with once monthly lokivetmab injections; the skin lesions improved but did not resolve. Conclusion and clinical importance Lokivetmab treatment was effective in resolving and maintaining pruritus remission in this dog with widespread cutaneous mast cell disease. Whether CM in dogs represent a separate entity that should be distinguished from a low‐grade MCT requires further investigation.

show abstract

Section: Discussionmentioning

confidence: 99%

Lokivetmab therapy for pruritus in a dog with cutaneous mastocytosis

Meichner

Kiupel

Kasantikul

et al. 2018

Veterinary Dermatology

View full text Add to dashboard Cite

show abstract

“…Symptoms such as urticaria, angioedema, flush, abdominal pain, diarrhea, hypotension, syncope, and musculoskeletal pain are caused by the release of MC mediators. 54,57 Binding of monomeric immunoglobulin (Ig) E to the FcεRI receptor induce survival of MCs in absence of antigens. 58,59 Furthermore, this receptor plays an important role in the protection of the organism against parasitic infections.…”

Section: Ma S T Cell Recep Tor S-b Le Ss Ing and Cur S E At The Sammentioning

confidence: 99%

Mast cells—Good guys with a bad image?

Meyer

Zenclussen

2018

American J Rep Immunol

View full text Add to dashboard Cite

show abstract

“…The main rationale for presentation of our patient is rare onset of adult-type mastocytosis in childhood and a relatively small The recent review and meta-analysis reported by Le et al indicate an even smaller percentage of remission of pediatric mastocytosis. 11 The complete resolution was found only in mastocytoma and maculopapular CM with complete resolution rate 10% and 1.9% per year, respectively. Up to this day, the relationship between the presence of D816V KIT mutation and persistence of CM until adult age remains unclear.…”

Section: Discussionmentioning

confidence: 91%

“…The recent review and meta‐analysis reported by Le et al . indicate an even smaller percentage of remission of pediatric mastocytosis . The complete resolution was found only in mastocytoma and maculopapular CM with complete resolution rate 10% and 1.9% per year, respectively.…”

Section: Discussionmentioning

confidence: 92%